Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques

BACKGROUND: Amyloid-β positivity (Aβ+) based on PET imaging is part of the enrollment criteria for many of the clinical trials of Alzheimer’s disease (AD), particularly in trials for amyloid-targeted therapy. Predicting Aβ positivity prior to PET imaging can decrease unnecessary patient burden and c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Alzheimers Dis
Autores principales: Ezzati, Ali, Harvey, Danielle J., Habeck, Christian, Golzar, Ashkan, Qureshi, Irfan A., Zammit, Andrea R., Hyun, Jinshil, Truelove-Hill, Monica, Hall, Charles B., Davatzikos, Christos, Lipton, Richard B.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7376527/
https://ncbi.nlm.nih.gov/pubmed/31884486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-191038
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares